Cosmos Health Inc. - Common Stock (COSM)
0.7080
+0.0467 (7.06%)
Cosmos Health Inc is a healthcare-focused company that specializes in providing innovative solutions and services across the pharmaceutical industry
The company primarily engages in the delivery of healthcare products, medical supplies, and related services, aiming to improve patient care and health outcomes. Cosmos Health is also involved in the development and distribution of generic and branded pharmaceuticals, emphasizing quality and accessibility. Through its various operations, the company seeks to create value for stakeholders while advancing healthcare delivery in diverse markets.
Previous Close | 0.6613 |
---|---|
Open | 0.6500 |
Bid | 0.6720 |
Ask | 0.7059 |
Day's Range | 0.6500 - 0.7200 |
52 Week Range | 0.4677 - 1.580 |
Volume | 204,712 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 736,268 |
News & Press Releases
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
CHICAGO, IL / ACCESS Newswire / January 28, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on January 27, 2025, its wholly owned subsidiary, CosmoFarm S.A. (the "Issuer" or "CosmoFarm"), entered into an agreement with a European bank to issue a €2,200,000 (approximately $2,293,830) secured bond (the "Loan").
Via ACCESS Newswire · January 28, 2025
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
CHICAGO, IL / ACCESS Newswire / January 27, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a new patent application for allergic inflammation, a condition characterized by immune system hypersensitivity.
Via ACCESS Newswire · January 27, 2025
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a supplemental exclusive distribution agreement with Virax Biolabs Group Limited NASDAQ:VRAXNASDAQVRAX)
Via ACCESS Newswire · January 23, 2025
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million
CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has secured buy-out rights and exclusive licensing for two patented anticancer drugs targeting, among others, prostate, ovarian, and colorectal cancers.
Via ACCESS Newswire · January 22, 2025
Why Cosmos Health Stock Is Moving Higher Wednesdaybenzinga.com
Cosmos Health announced that it continues to hold the right to distribute mpox real-time PCR detection kits under its agreement with Virax Biolabs
Via Benzinga · August 21, 2024
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.
Via ACCESS Newswire · January 21, 2025
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a distribution agreement with Virax Biolabs Group Limited NASDAQ: VRAXNASDAQVRAX)
Via ACCESSWIRE · January 13, 2025
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.
Via ACCESSWIRE · December 26, 2024
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, and CFO, George Terzis, increased their stake in the Company by approximately 343,122 common shares, valued at $200,000, based on the closing share price on Friday, December 20, 2024.
Via ACCESSWIRE · December 23, 2024
Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price
CHICAGO, IL / ACCESSWIRE / November 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that, on November 25, 2024, Taglich Brothers, Inc. ("Taglich") published an updated research report on the Company's common stock.
Via ACCESSWIRE · November 26, 2024
Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
CHICAGO, IL / ACCESSWIRE / November 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has adopted a strategy to include Bitcoin and Ethereum as part of its treasury reserve assets.
Via ACCESSWIRE · November 18, 2024
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ
Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.
Via ACCESSWIRE · November 14, 2024
Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.
Via ACCESSWIRE · November 12, 2024
Cosmos Health’s Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its healthcare distribution business, operated through its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), has achieved record sales.
Via ACCESSWIRE · November 1, 2024
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via News Direct · October 1, 2024
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by 160%, increasing to $596,000 year-to-date in 2024 from $230,000 during the same period in 2023.
Via ACCESSWIRE · September 25, 2024
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received its first round of purchase orders in the United Kingdom (UK) for its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ('C-Scrub'), exceeding $500,000. The orders cover the period from July 2024 to September 2024.
Via ACCESSWIRE · September 23, 2024
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an exclusivity agreement with Virax Biolabs to distribute mpox (formerly monkeypox) virus real-time PCR detection kits across India.
Via ACCESSWIRE · September 23, 2024
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
CHICAGO, IL / ACCESSWIRE / September 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders.
Via ACCESSWIRE · September 19, 2024
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments
CHICAGO, IL / ACCESSWIRE / September 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its updated guidance for the 2024-2027 period.
Via ACCESSWIRE · September 18, 2024
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
CHICAGO, IL / ACCESSWIRE / September 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on September 16, 2024, Taglich Brothers, Inc. ("Taglich Brothers") published its updated research report on the Company's common stock.
Via ACCESSWIRE · September 17, 2024
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs NASDAQ: VRAXNASDAQVRAX)
Via ACCESSWIRE · September 16, 2024
EXCLUSIVE: Virax Biolabs Inks Distribution Pact For Mpox Diagnostic Kits In Europe And Middle Eastbenzinga.com
Virax Biolabs has signed a distribution agreement to commercialize RT PCR Mpox virus detection kits in Europe and Gulf countries, amid a WHO-declared international health emergency due to rising mpox cases.
Via Benzinga · August 28, 2024
Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements
CHICAGO, IL / ACCESSWIRE / August 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that the Company has regained compliance with Listing Rule 5250(c)(1) (the "Filing Rule"), in connection with the filing of its 2023 Annual Report on Form 10-K (the "Annual Report") and its financial results for the first quarter ended March 31, 2024, on Form 10-Q (the "First Quarter Report").
Via ACCESSWIRE · August 23, 2024
Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE
CHICAGO, IL / ACCESSWIRE / July 3, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQCOSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has completed the latest upgrades to its manufacturing capabilities and capacities and secured a contract manufacturing agreement with Provident Pharmaceuticals ("Provident").
Via ACCESSWIRE · August 21, 2024